Covid-19 Impact on Global CAR-T Therapy in Haematological Malignancy Market Size, Status and Forecast 2020-2026

June 2020 | 92 pages | ID: C679AAEB69F8EN
QYResearch

Abstracts

CAR-T Therapy in Haematological Malignancy market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global CAR-T Therapy in Haematological Malignancy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the CAR-T Therapy in Haematological Malignancy market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyzes the impact of Coronavirus COVID-19 on the CAR-T Therapy in Haematological Malignancy industry.
The key players covered in this study

• Celgene (Juno Therapeutics)
• Novartis
• Gilead (Kite Pharma)
• Pfizer
• CARsgen Therapeutics
• Autolus Therapeutics
• Aurora BioPharma
• Sorrento Therapeutics
• Mustang Bio
• Bluebird Bio
• Collectis
• Allogene Therapeutics
• Celyad

Market segment by Type, the product can be split into

• Allogeneic
• Autologous

Market segment by Application, split into

• Hospitals
• Cancer Research Centers
• Others

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global CAR-T Therapy in Haematological Malignancy status, future forecast, growth opportunity, key market and key players.
• To present the CAR-T Therapy in Haematological Malignancy development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

To strategically profile the key players and comprehensively analyze their development plan and strategies.

• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of CAR-T Therapy in Haematological Malignancy are as follows:
History Year: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by CAR-T Therapy in Haematological Malignancy Revenue
1.4 Covid-19 Implications on Market by Type
  1.4.1 Global CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Allogeneic
  1.4.3 Autologous
1.5 Market by Application
  1.5.1 Global CAR-T Therapy in Haematological Malignancy Market Share by Application: 2020 VS 2026
  1.5.2 Hospitals
  1.5.3 Cancer Research Centers
  1.5.4 Others
1.6 Coronavirus Disease 2019 (Covid-19): CAR-T Therapy in Haematological Malignancy Industry Impact
  1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
  1.6.2 Covid-19 Impact: Commodity Prices Indices
  1.6.3 Covid-19 Impact: Global Major Government Policy
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS

2.1 Covid-19 Implications on Global CAR-T Therapy in Haematological Malignancy Market Perspective (2015-2026)
2.2 Covid-19 Implications on Global CAR-T Therapy in Haematological Malignancy Growth Trends by Regions
  2.2.1 CAR-T Therapy in Haematological Malignancy Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 CAR-T Therapy in Haematological Malignancy Historic Market Share by Regions (2015-2020)
  2.2.3 CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 CAR-T Therapy in Haematological Malignancy Market Growth Strategy
  2.3.6 Primary Interviews with Key CAR-T Therapy in Haematological Malignancy Players (Opinion Leaders)

3 COVID-19 IMPLICATIONS ON COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top CAR-T Therapy in Haematological Malignancy Players by Market Size
  3.1.1 Global Top CAR-T Therapy in Haematological Malignancy Players by Revenue (2015-2020)
  3.1.2 Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Players (2015-2020)
  3.1.3 Global CAR-T Therapy in Haematological Malignancy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global CAR-T Therapy in Haematological Malignancy Market Concentration Ratio
  3.2.1 Global CAR-T Therapy in Haematological Malignancy Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by CAR-T Therapy in Haematological Malignancy Revenue in 2019
3.3 CAR-T Therapy in Haematological Malignancy Key Players Head office and Area Served
3.4 Key Players CAR-T Therapy in Haematological Malignancy Product Solution and Service
3.5 Date of Enter into CAR-T Therapy in Haematological Malignancy Market
3.6 Mergers & Acquisitions, Expansion Plans

4 COVID-19 IMPLICATIONS ON MARKET SIZE BY TYPE (2015-2026)

4.1 Global CAR-T Therapy in Haematological Malignancy Historic Market Size by Type (2015-2020)
4.2 Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Type (2021-2026)

5 COVID-19 IMPLICATIONS ON MARKET SIZE BY APPLICATION (2015-2026)

5.1 Global CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)
5.2 Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA IMPACT OF COVID-19

6.1 North America CAR-T Therapy in Haematological Malignancy Market Size (2015-2020)
6.2 CAR-T Therapy in Haematological Malignancy Key Players in North America (2019-2020)
6.3 North America CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)
6.4 North America CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

7 EUROPE IMPACT OF COVID-19

7.1 Europe CAR-T Therapy in Haematological Malignancy Market Size (2015-2020)
7.2 CAR-T Therapy in Haematological Malignancy Key Players in Europe (2019-2020)
7.3 Europe CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)
7.4 Europe CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

8 CHINA IMPACT OF COVID-19

8.1 China CAR-T Therapy in Haematological Malignancy Market Size (2015-2020)
8.2 CAR-T Therapy in Haematological Malignancy Key Players in China (2019-2020)
8.3 China CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)
8.4 China CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

9 JAPAN IMPACT OF COVID-19

9.1 Japan CAR-T Therapy in Haematological Malignancy Market Size (2015-2020)
9.2 CAR-T Therapy in Haematological Malignancy Key Players in Japan (2019-2020)
9.3 Japan CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)
9.4 Japan CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

10 SOUTHEAST ASIA IMPACT OF COVID-19

10.1 Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size (2015-2020)
10.2 CAR-T Therapy in Haematological Malignancy Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)
10.4 Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

11 INDIA IMPACT OF COVID-19

11.1 India CAR-T Therapy in Haematological Malignancy Market Size (2015-2020)
11.2 CAR-T Therapy in Haematological Malignancy Key Players in India (2019-2020)
11.3 India CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)
11.4 India CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA IMPACT OF COVID-19

12.1 Central & South America CAR-T Therapy in Haematological Malignancy Market Size (2015-2020)
12.2 CAR-T Therapy in Haematological Malignancy Key Players in Central & South America (2019-2020)
12.3 Central & South America CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)
12.4 Central & South America CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

13KEY PLAYERS PROFILES

13.1 Celgene (Juno Therapeutics)
  13.1.1 Celgene (Juno Therapeutics) Company Details
  13.1.2 Celgene (Juno Therapeutics) Business Overview and Its Total Revenue
  13.1.3 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Introduction
  13.1.4 Celgene (Juno Therapeutics) Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020))
  13.1.5 Celgene (Juno Therapeutics) Recent Development and Reaction to COVID-19
13.2 Novartis
  13.2.1 Novartis Company Details
  13.2.2 Novartis Business Overview and Its Total Revenue
  13.2.3 Novartis CAR-T Therapy in Haematological Malignancy Introduction
  13.2.4 Novartis Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
  13.2.5 Novartis Recent Development and Reaction to COVID-19
13.3 Gilead (Kite Pharma)
  13.3.1 Gilead (Kite Pharma) Company Details
  13.3.2 Gilead (Kite Pharma) Business Overview and Its Total Revenue
  13.3.3 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Introduction
  13.3.4 Gilead (Kite Pharma) Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
  13.3.5 Gilead (Kite Pharma) Recent Development and Reaction to COVID-19
13.4 Pfizer
  13.4.1 Pfizer Company Details
  13.4.2 Pfizer Business Overview and Its Total Revenue
  13.4.3 Pfizer CAR-T Therapy in Haematological Malignancy Introduction
  13.4.4 Pfizer Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
  13.4.5 Pfizer Recent Development and Reaction to COVID-19
13.5 CARsgen Therapeutics
  13.5.1 CARsgen Therapeutics Company Details
  13.5.2 CARsgen Therapeutics Business Overview and Its Total Revenue
  13.5.3 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Introduction
  13.5.4 CARsgen Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
  13.5.5 CARsgen Therapeutics Recent Development and Reaction to COVID-19
13.6 Autolus Therapeutics
  13.6.1 Autolus Therapeutics Company Details
  13.6.2 Autolus Therapeutics Business Overview and Its Total Revenue
  13.6.3 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Introduction
  13.6.4 Autolus Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
  13.6.5 Autolus Therapeutics Recent Development and Reaction to COVID-19
13.7 Aurora BioPharma
  13.7.1 Aurora BioPharma Company Details
  13.7.2 Aurora BioPharma Business Overview and Its Total Revenue
  13.7.3 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Introduction
  13.7.4 Aurora BioPharma Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
  13.7.5 Aurora BioPharma Recent Development and Reaction to COVID-19
13.8 Sorrento Therapeutics
  13.8.1 Sorrento Therapeutics Company Details
  13.8.2 Sorrento Therapeutics Business Overview and Its Total Revenue
  13.8.3 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Introduction
  13.8.4 Sorrento Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
  13.8.5 Sorrento Therapeutics Recent Development and Reaction to COVID-19
13.9 Mustang Bio
  13.9.1 Mustang Bio Company Details
  13.9.2 Mustang Bio Business Overview and Its Total Revenue
  13.9.3 Mustang Bio CAR-T Therapy in Haematological Malignancy Introduction
  13.9.4 Mustang Bio Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
  13.9.5 Mustang Bio Recent Development and Reaction to COVID-19
13.10 Bluebird Bio
  13.10.1 Bluebird Bio Company Details
  13.10.2 Bluebird Bio Business Overview and Its Total Revenue
  13.10.3 Bluebird Bio CAR-T Therapy in Haematological Malignancy Introduction
  13.10.4 Bluebird Bio Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
  13.10.5 Bluebird Bio Recent Development and Reaction to COVID-19
13.11 Collectis
  10.11.1 Collectis Company Details
  10.11.2 Collectis Business Overview and Its Total Revenue
  10.11.3 Collectis CAR-T Therapy in Haematological Malignancy Introduction
  10.11.4 Collectis Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
  10.11.5 Collectis Recent Development and Reaction to COVID-19
13.12 Allogene Therapeutics
  10.12.1 Allogene Therapeutics Company Details
  10.12.2 Allogene Therapeutics Business Overview and Its Total Revenue
  10.12.3 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Introduction
  10.12.4 Allogene Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
  10.12.5 Allogene Therapeutics Recent Development and Reaction to COVID-19
13.13 Celyad
  10.13.1 Celyad Company Details
  10.13.2 Celyad Business Overview and Its Total Revenue
  10.13.3 Celyad CAR-T Therapy in Haematological Malignancy Introduction
  10.13.4 Celyad Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
  10.13.5 Celyad Recent Development and Reaction to COVID-19

14ANALYST'S VIEWPOINTS/CONCLUSIONS

15APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. CAR-T Therapy in Haematological Malignancy Key Market Segments
Table 2. Key Players Covered: Ranking by CAR-T Therapy in Haematological Malignancy Revenue
Table 3. Ranking of Global Top CAR-T Therapy in Haematological Malignancy Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Allogeneic
Table 6. Key Players of Autologous
Table 7. COVID-19 Impact Global Market: (Four CAR-T Therapy in Haematological Malignancy Market Size Forecast Scenarios)
Table 8. Opportunities and Trends for CAR-T Therapy in Haematological Malignancy Players in the COVID-19 Landscape
Table 9. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 10. Key Regions/Countries Measures against Covid-19 Impact
Table 11. Proposal for CAR-T Therapy in Haematological Malignancy Players to Combat Covid-19 Impact
Table 12. Global CAR-T Therapy in Haematological Malignancy Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 13. Global CAR-T Therapy in Haematological Malignancy Market Size by Regions (US$ Million): 2020 VS 2026
Table 14. Global CAR-T Therapy in Haematological Malignancy Market Size by Regions (2015-2020) (US$ Million)
Table 15. Global CAR-T Therapy in Haematological Malignancy Market Share by Regions (2015-2020)
Table 16. Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 17. Global CAR-T Therapy in Haematological Malignancy Market Share by Regions (2021-2026)
Table 18. Market Top Trends
Table 19. Key Drivers: Impact Analysis
Table 20. Key Challenges
Table 21. CAR-T Therapy in Haematological Malignancy Market Growth Strategy
Table 22. Main Points Interviewed from Key CAR-T Therapy in Haematological Malignancy Players
Table 23. Global CAR-T Therapy in Haematological Malignancy Revenue by Players (2015-2020) (Million US$)
Table 24. Global CAR-T Therapy in Haematological Malignancy Market Share by Players (2015-2020)
Table 25. Global Top CAR-T Therapy in Haematological Malignancy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in CAR-T Therapy in Haematological Malignancy as of 2019)
Table 26. Global CAR-T Therapy in Haematological Malignancy by Players Market Concentration Ratio (CR5 and HHI)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players CAR-T Therapy in Haematological Malignancy Product Solution and Service
Table 29. Date of Enter into CAR-T Therapy in Haematological Malignancy Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020) (Million US$)
Table 32. Global CAR-T Therapy in Haematological Malignancy Market Size Share by Type (2015-2020)
Table 33. Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Type (2021-2026)
Table 34. Global CAR-T Therapy in Haematological Malignancy Market Size Share by Application (2015-2020)
Table 35. Global CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020) (Million US$)
Table 36. Global CAR-T Therapy in Haematological Malignancy Market Size Share by Application (2021-2026)
Table 37. North America Key Players CAR-T Therapy in Haematological Malignancy Revenue (2019-2020) (Million US$)
Table 38. North America Key Players CAR-T Therapy in Haematological Malignancy Market Share (2019-2020)
Table 39. North America CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020) (Million US$)
Table 40. North America CAR-T Therapy in Haematological Malignancy Market Share by Type (2015-2020)
Table 41. North America CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020) (Million US$)
Table 42. North America CAR-T Therapy in Haematological Malignancy Market Share by Application (2015-2020)
Table 43. Europe Key Players CAR-T Therapy in Haematological Malignancy Revenue (2019-2020) (Million US$)
Table 44. Europe Key Players CAR-T Therapy in Haematological Malignancy Market Share (2019-2020)
Table 45. Europe CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020) (Million US$)
Table 46. Europe CAR-T Therapy in Haematological Malignancy Market Share by Type (2015-2020)
Table 47. Europe CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020) (Million US$)
Table 48. Europe CAR-T Therapy in Haematological Malignancy Market Share by Application (2015-2020)
Table 49. China Key Players CAR-T Therapy in Haematological Malignancy Revenue (2019-2020) (Million US$)
Table 50. China Key Players CAR-T Therapy in Haematological Malignancy Market Share (2019-2020)
Table 51. China CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020) (Million US$)
Table 52. China CAR-T Therapy in Haematological Malignancy Market Share by Type (2015-2020)
Table 53. China CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020) (Million US$)
Table 54. China CAR-T Therapy in Haematological Malignancy Market Share by Application (2015-2020)
Table 55. Japan Key Players CAR-T Therapy in Haematological Malignancy Revenue (2019-2020) (Million US$)
Table 56. Japan Key Players CAR-T Therapy in Haematological Malignancy Market Share (2019-2020)
Table 57. Japan CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020) (Million US$)
Table 58. Japan CAR-T Therapy in Haematological Malignancy Market Share by Type (2015-2020)
Table 59. Japan CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020) (Million US$)
Table 60. Japan CAR-T Therapy in Haematological Malignancy Market Share by Application (2015-2020)
Table 61. Southeast Asia Key Players CAR-T Therapy in Haematological Malignancy Revenue (2019-2020) (Million US$)
Table 62. Southeast Asia Key Players CAR-T Therapy in Haematological Malignancy Market Share (2019-2020)
Table 63. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020) (Million US$)
Table 64. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Share by Type (2015-2020)
Table 65. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020) (Million US$)
Table 66. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Share by Application (2015-2020)
Table 67. India Key Players CAR-T Therapy in Haematological Malignancy Revenue (2019-2020) (Million US$)
Table 68. India Key Players CAR-T Therapy in Haematological Malignancy Market Share (2019-2020)
Table 69. India CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020) (Million US$)
Table 70. India CAR-T Therapy in Haematological Malignancy Market Share by Type (2015-2020)
Table 71. India CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020) (Million US$)
Table 72. India CAR-T Therapy in Haematological Malignancy Market Share by Application (2015-2020)
Table 73. Central & South America Key Players CAR-T Therapy in Haematological Malignancy Revenue (2019-2020) (Million US$)
Table 74. Central & South America Key Players CAR-T Therapy in Haematological Malignancy Market Share (2019-2020)
Table 75. Central & South America CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020) (Million US$)
Table 76. Central & South America CAR-T Therapy in Haematological Malignancy Market Share by Type (2015-2020)
Table 77. Central & South America CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020) (Million US$)
Table 78. Central & South America CAR-T Therapy in Haematological Malignancy Market Share by Application (2015-2020)
Table 79. Celgene (Juno Therapeutics) Company Details
Table 80. Celgene (Juno Therapeutics) Business Overview
Table 81. Celgene (Juno Therapeutics) Product
Table 82. Celgene (Juno Therapeutics) Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020) (Million US$)
Table 83. Celgene (Juno Therapeutics) Recent Development
Table 84. Novartis Company Details
Table 85. Novartis Business Overview
Table 86. Novartis Product
Table 87. Novartis Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020) (Million US$)
Table 88. Novartis Recent Development
Table 89. Gilead (Kite Pharma) Company Details
Table 90. Gilead (Kite Pharma) Business Overview
Table 91. Gilead (Kite Pharma) Product
Table 92. Gilead (Kite Pharma) Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020) (Million US$)
Table 93. Gilead (Kite Pharma) Recent Development
Table 94. Pfizer Company Details
Table 95. Pfizer Business Overview
Table 96. Pfizer Product
Table 97. Pfizer Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020) (Million US$)
Table 98. Pfizer Recent Development
Table 99. CARsgen Therapeutics Company Details
Table 100. CARsgen Therapeutics Business Overview
Table 101. CARsgen Therapeutics Product
Table 102. CARsgen Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020) (Million US$)
Table 103. CARsgen Therapeutics Recent Development
Table 104. Autolus Therapeutics Company Details
Table 105. Autolus Therapeutics Business Overview
Table 106. Autolus Therapeutics Product
Table 107. Autolus Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020) (Million US$)
Table 108. Autolus Therapeutics Recent Development
Table 109. Aurora BioPharma Company Details
Table 110. Aurora BioPharma Business Overview
Table 111. Aurora BioPharma Product
Table 112. Aurora BioPharma Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020) (Million US$)
Table 113. Aurora BioPharma Recent Development
Table 114. Sorrento Therapeutics Business Overview
Table 115. Sorrento Therapeutics Product
Table 116. Sorrento Therapeutics Company Details
Table 117. Sorrento Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020) (Million US$)
Table 118. Sorrento Therapeutics Recent Development
Table 119. Mustang Bio Company Details
Table 120. Mustang Bio Business Overview
Table 121. Mustang Bio Product
Table 122. Mustang Bio Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020) (Million US$)
Table 123. Mustang Bio Recent Development
Table 124. Bluebird Bio Company Details
Table 125. Bluebird Bio Business Overview
Table 126. Bluebird Bio Product
Table 127. Bluebird Bio Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020) (Million US$)
Table 128. Bluebird Bio Recent Development
Table 129. Collectis Company Details
Table 130. Collectis Business Overview
Table 131. Collectis Product
Table 132. Collectis Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020) (Million US$)
Table 133. Collectis Recent Development
Table 134. Allogene Therapeutics Company Details
Table 135. Allogene Therapeutics Business Overview
Table 136. Allogene Therapeutics Product
Table 137. Allogene Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020) (Million US$)
Table 138. Allogene Therapeutics Recent Development
Table 139. Celyad Company Details
Table 140. Celyad Business Overview
Table 141. Celyad Product
Table 142. Celyad Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020) (Million US$)
Table 143. Celyad Recent Development
Table 144. Research Programs/Design for This Report
Table 145. Key Data Information from Secondary Sources
Table 146. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global CAR-T Therapy in Haematological Malignancy Market Share by Type: 2020 VS 2026
Figure 2. Allogeneic Features
Figure 3. Autologous Features
Figure 4. Global CAR-T Therapy in Haematological Malignancy Market Share by Application: 2020 VS 2026
Figure 5. Hospitals Case Studies
Figure 6. Cancer Research Centers Case Studies
Figure 7. Others Case Studies
Figure 8. CAR-T Therapy in Haematological Malignancy Report Years Considered
Figure 9. Global CAR-T Therapy in Haematological Malignancy Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global CAR-T Therapy in Haematological Malignancy Market Share by Regions: 2020 VS 2026
Figure 11. Global CAR-T Therapy in Haematological Malignancy Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global CAR-T Therapy in Haematological Malignancy Market Share by Players in 2019
Figure 14. Global Top CAR-T Therapy in Haematological Malignancy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in CAR-T Therapy in Haematological Malignancy as of 2019
Figure 15. The Top 10 and 5 Players Market Share by CAR-T Therapy in Haematological Malignancy Revenue in 2019
Figure 16. North America CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America CAR-T Therapy in Haematological Malignancy Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Celgene (Juno Therapeutics) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 24. Celgene (Juno Therapeutics) Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
Figure 25. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 26. Novartis Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
Figure 27. Gilead (Kite Pharma) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. Gilead (Kite Pharma) Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
Figure 29. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Pfizer Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
Figure 31. CARsgen Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. CARsgen Therapeutics Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
Figure 33. Autolus Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Autolus Therapeutics Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
Figure 35. Aurora BioPharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Aurora BioPharma Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
Figure 37. Sorrento Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Sorrento Therapeutics Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
Figure 39. Mustang Bio Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Mustang Bio Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
Figure 41. Bluebird Bio Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Bluebird Bio Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
Figure 43. Collectis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Collectis Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
Figure 45. Allogene Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. Allogene Therapeutics Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
Figure 47. Celyad Total Revenue (US$ Million): 2019 Compared with 2018
Figure 48. Celyad Revenue Growth Rate in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
Figure 49. Bottom-up and Top-down Approaches for This Report
Figure 50. Data Triangulation
Figure 51. Key Executives Interviewed